Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Therapy resistance on the RADar in ovarian cancer

Jonas Schwickert1,2,3, Franziska M Zickgraf1,2, Martin R Sprick1,2

  • 1Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

EMBO Molecular Medicine
|March 29, 2021
PubMed

Insights

RAD51 expression can predict platinum resistance in high-grade serous ovarian cancer (HGSOC). This finding helps identify patients who may not respond to standard chemotherapy, guiding personalized treatment strategies for ovarian cancer.

Area of Science:

  • Gynecologic Oncology
  • Cancer Biomarkers
  • Chemotherapy Resistance

Background:

  • High-grade serous ovarian cancer (HGSOC) has a poor prognosis among gynecological cancers.
  • Therapy resistance is a significant challenge in HGSOC treatment.
  • Identifying biomarkers for treatment response is crucial for patient outcomes.

Purpose of the Study:

  • To investigate RAD51 expression as a potential biomarker for platinum resistance in HGSOC.
  • To evaluate the clinical utility of RAD51 in predicting treatment outcomes for ovarian cancer patients.

Main Methods:

  • Analysis of RAD51 expression levels in HGSOC patient samples.
  • Correlation of RAD51 expression with response to platinum-based chemotherapy.
  • Statistical analysis to determine the predictive value of RAD51.

Main Results:

  • RAD51 expression was found to be a significant biomarker of platinum resistance in HGSOC.
  • Elevated RAD51 levels were associated with poorer response to platinum chemotherapy.
  • This suggests a mechanism underlying therapy resistance in ovarian cancer.

Conclusions:

  • RAD51 expression serves as a predictive biomarker for platinum resistance in high-grade serous ovarian cancer.
  • This finding can aid in selecting effective therapies and improving treatment strategies for HGSOC patients.
  • Further research can explore therapeutic targeting of RAD51 in resistant ovarian cancer.

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.6K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
67.4K